Cocrystal Pharma Q2 2022 Earnings Report
Key Takeaways
Cocrystal Pharma reported a net loss of $24.4 million, or $0.25 per share, for the second quarter of 2022, which included a non-cash impairment charge of $19.1 million. The company's cash balance was $51.0 million as of June 30, 2022, and they believe it is sufficient to fund planned operations into 2024.
Advanced compounds in the clinic and announced a significant research collaboration.
Designed Phase 2a human challenge study with oral PB2 inhibitor CC-42344 to evaluate antiviral efficacy and tolerability.
Expect to report results from Phase 1 study in healthy volunteers underway in Australia later this year.
Initiated API synthesis and process chemistry development with novel, broad-spectrum COVID-19 intranasal/pulmonary and oral protease inhibitors.
Cocrystal Pharma
Cocrystal Pharma
Forward Guidance
Cocrystal Pharma's forward-looking statements involve initiating two Phase 1 studies for COVID-19 programs in 2022, reporting Phase 1 Influenza A product candidate data later in 2022, and filing with the UK regulatory agency for a Phase 2a study in 2023.